Skip to main content
. 2019 Jun 17;46(9):1840–1849. doi: 10.1007/s00259-019-04377-6

Table 2.

Effect of viewing the 18F-FDG-PET on manual tumor delineation on immuno-PET and success rate of semi-automatic delineation

Measure 89Zr-rituximab 89Zr-cetuximab 89Zr-trastuzumab All
D3 D6 D3 D6 D4
% of VOI changed by ≥1 observer after viewing the 18F-FDG-PET 19% 34% 0% 10% 31%a 25%
% of VOI accepted after semi-automatic delineation 58% 66% 14% 30% 21% 45%

aNo 18F-FDG-PET available for patient 17